Current Pharmacologic Options and Emerging Therapeutic Approaches for the Management of Ulcerative Colitis: A Narrative Review.
| Autor: | Sebastian SA; Department of Internal Medicine Edgemont Medical Centre, Calgary, Canada., Kaiwan O; Department of Medicine Northeast Ohio Medical University, USA., Co EL; Department of Internal Medicine University of Santo Tomas, Manila., Mehendale M; Smolensk State Medical University, Russia Department of Internal Medicine., Mohan BP; Department of Gastroenterology University of Utah School of Medicine, Utah, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Spartan medical research journal [Spartan Med Res J] 2024 Sep 09; Vol. 9 (3), pp. 123397. Date of Electronic Publication: 2024 Sep 09 (Print Publication: 2024). |
| DOI: | 10.51894/001c.123397 |
| Abstrakt: | Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disorder (IBD) with periods of relapse and remission. Current advancements in clinical research have led to the development of more refined and effective medical therapy for UC. Summary of the Evidence: Traditional therapeutic agents such as 5-aminosalicylates (5-ASAs), sulfasalazine (SASP), corticosteroids, and immunomodulatory drugs have remained the gold standard for decades. However, their novel formulations and dosage regimens have changed their sequences in the medical management of UC. Several other novel drugs are in the final phases of clinical development or have recently received regulatory approval designed to target specific mechanisms involved in the inflammatory cascade for UC. Conclusions: This narrative review sought to provide a comprehensive knowledge of the potential benefits of standard and emerging therapies, including novel formulations, new chemical entities, and novel therapeutic approaches in managing UC. Keywords: Ulcerative colitis, 5- Aminosalicylic acid, sulfasalazine, corticosteroids, biologics, immunomodulators, novel formulations. Competing Interests: None |
| Databáze: | MEDLINE |
| Externí odkaz: |
|